Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.
Caribou Biosciences, Inc.
AvenCell Therapeutics, Inc.
Dren Bio
Allogene Therapeutics
BeOne Medicines
Gamida Cell ltd
Ossium Health, Inc.
Hutchmed
Vironexis Biotherapeutics Inc.
GeoVax, Inc.
Adela, Inc
Umoja Biopharma
Acerta Pharma BV
Incyte Corporation
Fate Therapeutics
CRISPR Therapeutics
AVM Biotechnology Inc
CRISPR Therapeutics
Incyte Corporation
Biotroy Therapeutics
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Ossium Health, Inc.
Hebei Senlang Biotechnology Inc., Ltd.
Bristol-Myers Squibb
Tempus AI
Celgene
Hangzhou Sumgen Biotech Co., Ltd.
Nurix Therapeutics, Inc.
Ono Pharmaceutical Co. Ltd
Daiichi Sankyo
Kymera Therapeutics, Inc.
Beam Therapeutics Inc.
Zhejiang DTRM Biopharma
Boehringer Ingelheim
Munich Leukemia Laboratory
Takeda
BeiGene
Servier
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Pfizer
OrphAI Therapeutics
Celgene
Kyowa Kirin Co., Ltd.
Altor BioScience
MitoImmune Therapeutics
Pack Health
Sanguine Biosciences